GREENWICH LIFESCIENCES, INC. Current Assets
GREENWICH LIFESCIENCES, INC. (GLSI) had Current Assets of $8.88 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-11
- 2026-06-30: Assets, Current $8.88M.
- 2026-03-31: Assets, Current $10.51M.
- 2025-12-31: Assets, Current $6.18M.
- 2024-12-31: Assets, Current $4.09M.
| Period end | Assets, Current |
|---|---|
| 2026-06-30 | $8.88M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $10.51M 10-Q · filed 2026-06-04 |
| 2025-12-31 | $6.18M 10-Q · filed 2026-08-11 |
| 2024-12-31 | $4.09M 10-K · filed 2026-06-01 |
| 2021-09-30 | $28.91M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $29.80M 10-Q · filed 2021-08-13 |
| 2021-03-31 | $30.40M 10-Q · filed 2021-05-20 |
| 2020-12-31 | $28.66M 10-Q · filed 2021-11-15 |
| 2020-09-30 | $6.26M 10-Q · filed 2020-11-16 |
| 2019-12-31 | $6.83K 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |